سعر تروليسيتي Trulicity‏ 1.5مجم/0.5مل 4 اقلام 2026

Trulicity (dulaglutide) 1.5 mg/0.5 ml single-dose pre-filled pens for subcutaneous injection, pack of 4 (one month of weekly doses); Eli Lilly, imported by Egyptian Pharmex. GLP-1 receptor agonist for type 2 diabetes.

• Most common adverse reactions (incidence 5% or more): nausea, diarrhea, vomiting, abdominal pain and decreased appetite. Gastrointestinal adverse reactions occurred in 21% with placebo, 32% with 0.75 mg and 41% with 1.5 mg in placebo-controlled trials; dyspepsia and constipation were also reported.International label, same product · DailyMed (US National Library of Medicine)
• Other reported findings include a mean heart-rate increase of 2-4 beats per minute, PR-interval prolongation and first-degree AV block, and elevations of pancreatic enzymes (lipase, amylase).International label, same product · DailyMed (US National Library of Medicine)

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).International label, same product · DailyMed (US National Library of Medicine)
• Serious hypersensitivity reaction to dulaglutide or any product component.International label, same product · DailyMed (US National Library of Medicine)

• Boxed warning: dulaglutide causes thyroid C-cell tumors in rodents; human relevance is unknown. Contraindicated with personal/family history of MTC or MEN 2; counsel patients about symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness).International label, same product · DailyMed (US National Library of Medicine)
• Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported with GLP-1 receptor agonists; discontinue promptly if suspected and do not restart if confirmed.International label, same product · DailyMed (US National Library of Medicine)
• Risk of hypoglycemia when used with an insulin secretagogue (e.g. a sulfonylurea) or insulin; a lower dose of the secretagogue or insulin may be needed.International label, same product · DailyMed (US National Library of Medicine)

• Oral medications (especially those with a narrow therapeutic index, e.g. warfarin)Dulaglutide delays gastric emptying and may affect absorption of concomitant oral medications; monitor drugs with a narrow therapeutic index (e.g. INR with warfarin).DailyMed (US National Library of Medicine)
• Insulin and insulin secretagogues (e.g. sulfonylureas)Increased risk of hypoglycemia; consider reducing the dose of the insulin secretagogue or insulin.DailyMed (US National Library of Medicine)

• Limited human data are insufficient to determine a drug-associated risk; in pregnant rats and rabbits, embryonic deaths, fetal growth reductions and fetal abnormalities occurred at exposures 5-6 times or more the human exposure at the maximum dose. Use in pregnancy only if the potential benefit justifies the potential risk to the fetus; poorly controlled diabetes itself carries pregnancy risks.International label, same product · DailyMed (US National Library of Medicine)
• No data on the presence of dulaglutide in human milk, effects on the breastfed infant or milk production; weigh benefits of breastfeeding against the mother's need for the drug.International label, same product · DailyMed (US National Library of Medicine)

• Dulaglutide: GLP-1 receptor agonist: increases glucose-dependent insulin secretion, decreases glucagon secretion and slows gastric emptying.